Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Real-Time Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
02607 SH PHARMA
RTNominal up14.200 +0.120 (+0.852%)
Others

10/09/2019 15:48

{I-bank focus}Morgan cuts Shanghai Pharma (02607) to HK$17.1

[ET Net News Agency, 10 September 2019] Morgan Stanley lowered its target price for
Shanghai Pharmaceutical (SPH)(02607) to HK$17.1 from HK$21.5 and maintained its
"equal-weight" rating.
The research house said SPH's distribution and manufacturing segments are showing stable
growth, driven by innovative products and effective hospital promotion. Morgan is more
bullish on the top line but cut earnings estimates slightly to reflect higher expenses.
It raised overall revenue forecasts by 2.5% for 2019, 4.2% for 2020, and 3.3% for 2021.
The increases came from both distribution and manufacturing. Spending on sales and
marketing, however, rose in 1H, and Morgan raised costs a bit to reflect more product
launches ahead.
Overall, it trimmed its earnings estimates by 3.9% for 2019, 3.4% for 2020, and 0.9% for
2021. Morgan's earnings CAGR is 8.7% (2018-2021). (KL)

Remark: Real time quote last updated: 06/12/2019 17:59
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2019 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.